FDA Clearance May Thwart Monograph Goal; Ganley Talks Turkey About ONP
This article was originally published in The Tan Sheet
Executive Summary
The Office of Nonprescription Products' goal of completing all OTC monographs by 2010 is viable only if FDA improves its document clearance process, according to ONP head Charles Ganley, MD
You may also be interested in...
NDAC Calls For Predefined Endpoints In Consumer Behavior Trials
Rx-to-OTC switch sponsors will be expected to work with FDA to establish predefined endpoints for each consumer behavior trial they plan, if the agency follows advice given by the Nonprescription Drugs Advisory Committee during a Sept. 25 meeting
Actual Use, Label Comprehension Guidances Slated For 2006
Guidances under development in 2006 reflect FDA's interest in improving the quality of Rx-to-OTC switch submissions
ONP: Leaner, Meaner In 2006
Director of the Office of Nonprescription Products Charles Ganley, MD, and Assistant Director Susan Johnson, PhD, met with industry stakeholders at a conference Feb. 1 to present an overview of the status of ONP in 2006. The department heads discussed FDA's plans to set a final deadline on monograph clearance and improve internal communication and NDA review, and made several suggestions on how industry can help FDA do its job..